Carbosin 150 mg inf. sol. (conc.) i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

carbosin 150 mg inf. sol. (conc.) i.v. vial

teva pharma belgium sa-nv - carboplatin 10 mg/ml - concentrate for solution for infusion - 150 mg - carboplatin 10 mg/ml - carboplatin

Stricarb 10 mg/mL (150 mg/15 mL) Solution for Infusion (IV) Philippines - English - FDA (Food And Drug Administration)

stricarb 10 mg/ml (150 mg/15 ml) solution for infusion (iv)

mylan philippines inc. - carboplatin - solution for infusion (iv) - 10 mg/ml (150 mg/15 ml)

Carboplatinum Hikma Farmacêutica 50 mg inf. sol. (conc.) i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

carboplatinum hikma farmacêutica 50 mg inf. sol. (conc.) i.v. vial

hikma farmacêutica s.a. - carboplatin 10 mg/ml - concentrate for solution for infusion - 10 mg/ml - carboplatin 50 mg - carboplatin

Carboplatinum Hikma Farmacêutica 150 mg inf. sol. (conc.) i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

carboplatinum hikma farmacêutica 150 mg inf. sol. (conc.) i.v. vial

hikma farmacêutica s.a. - carboplatin 10 mg/ml - concentrate for solution for infusion - 10 mg/ml - carboplatin 150 mg - carboplatin

Carboplatinum Hikma Farmacêutica 450 mg inf. sol. (conc.) i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

carboplatinum hikma farmacêutica 450 mg inf. sol. (conc.) i.v. vial

hikma farmacêutica s.a. - carboplatin 10 mg/ml - concentrate for solution for infusion - 10 mg/ml - carboplatin 450 mg - carboplatin

CARBOPLATIN injection, solution United States - English - NLM (National Library of Medicine)

carboplatin injection, solution

sagent pharmaceuticals - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin 10 mg in 1 ml - carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor <2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously trea